sarpogrelate has been researched along with eicosapentaenoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, M | 1 |
| Ito, T; Nomura, S; Okuda, Y; Omoto, S; Shouzu, A; Suzuki, M; Taniura, T | 1 |
2 trial(s) available for sarpogrelate and eicosapentaenoic acid
| Article | Year |
|---|---|
The NMatrix, a new method of presenting statistics, displays the characteristics of medicines with similar effects used in the treatment of lumbar spinal stenosis concisely and clearly, facilitating the selection of appropriate medications.
Topics: Aged; Aged, 80 and over; alpha-Cyclodextrins; Alprostadil; Decision Making; Eicosapentaenoic Acid; Epoprostenol; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Pain Measurement; Platelet Aggregation Inhibitors; Sciatica; Spinal Stenosis; Succinates; Treatment Outcome | 2015 |
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
Topics: Adiponectin; Aged; Aged, 80 and over; Ankle Brachial Index; Arteriosclerosis Obliterans; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Quinolines; Risk Factors; Succinates; Time Factors; Treatment Outcome | 2018 |